G

Glenmark Pharmaceuticals Ltd
NSE:GLENMARK

Watchlist Manager
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Watchlist
Price: 1 535.8 INR -1.11% Market Closed
Market Cap: 433.4B INR
Have any thoughts about
Glenmark Pharmaceuticals Ltd?
Write Note

Operating Margin
Glenmark Pharmaceuticals Ltd

7.8%
Current
11%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
7.8%
=
Operating Profit
9.5B
/
Revenue
122.5B

Operating Margin Across Competitors

Country IN
Market Cap 433.4B INR
Operating Margin
8%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 756.2B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.7T DKK
Operating Margin
44%
Country US
Market Cap 350.6B USD
Operating Margin
28%
Country US
Market Cap 252B USD
Operating Margin
34%
Country CH
Market Cap 200.1B CHF
Operating Margin
32%
Country UK
Market Cap 161.8B GBP
Operating Margin
21%
Country CH
Market Cap 171.5B CHF
Operating Margin
31%
Country US
Market Cap 151.5B USD
Operating Margin
22%
No Stocks Found

Glenmark Pharmaceuticals Ltd
Glance View

Market Cap
433.4B INR
Industry
Pharmaceuticals

Glenmark Pharmaceuticals Ltd., founded in 1977 by Gracias Saldanha, has crafted its journey from a single-product company to a noteworthy player in the global pharmaceutical landscape. Headquartered in Mumbai, India, its growth has been driven by a formidable strategy of focusing on both generics and novel drug discovery. In the fiercely competitive world of pharmaceuticals, Glenmark carved its niche by building a diverse product portfolio that spans across dermatology, respiratory, and oncology segments, among others. The company’s nuanced understanding of therapeutic areas and its pursuit of complex generics have empowered it to not only tap into established markets but also venture into emerging ones across 80 countries. This international strategy, combined with robust research and development infrastructure, underscores how Glenmark leverages scientific innovation to ensure steady revenue streams. At the heart of Glenmark's operations lies its commitment to research-driven growth. The company allocates significant resources to its R&D initiatives, manifesting in state-of-the-art facilities across India, Switzerland, and the U.S. Through these centers, Glenmark focuses on the development of differentiated generic medicines and the discovery of innovative therapeutic molecules. The synergy between its generic and innovative drug segments enables Glenmark to sustain profitability by capitalizing on patent expiries while simultaneously pioneering novel drug therapies. This dual approach not only helps the company secure a competitive position in the pharmaceutical market but also fuels its earnings through a balanced mix of volume-driven sales and premium pricing of differentiated products.

GLENMARK Intrinsic Value
1 053.31 INR
Overvaluation 31%
Intrinsic Value
Price
G

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
7.8%
=
Operating Profit
9.5B
/
Revenue
122.5B
What is the Operating Margin of Glenmark Pharmaceuticals Ltd?

Based on Glenmark Pharmaceuticals Ltd's most recent financial statements, the company has Operating Margin of 7.8%.